KRAS and cancer: Unexpectedly, we find no correlation between anti-mitotic drug response and KRAS status in archival analysis of over 600 cancer cell lines, in experimental comparison of a panel of 5 KRAS-wild-type and 10 KRAS-mutant cancer cell lines, or when measuring induction of apoptotic cell death in three independent isogenic paired cell lines treated with anti-mitotic drugs (see Fig. 5 and Supplementary Figs S9 and S10).